Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine Plus Luspatercept vs Azacitidine in Higher-risk MDS
NCT06927232Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2025
- Primary completion
- Jan 2026
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 3 trial of luspatercept in myelodysplastic syndrome (MDS), sponsored by Peking Union Medical College Hospital. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06927232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06927232.